Intervention With a GABA Supplement in Prediabetics

The Effects of a GABA Supplement Versus a Placebo on Glucose Tolerance and Blood Pressure in Prediabetics

In this double-blind parallel placebo controlled intervention study the effects of 3 times daily 500 mg gamma-aminobutyric acid (GABA) supplementation on glucose tolerance and cardiovascular health will be assessed in prediabetics.

Inclusion Criteria:

• Age between 50 and 70
• BMI higher or equal to 27 kg/m2
• Impaired fasting glucose (fasting glucose ≥ 6.1 and ≤ 6.9 mmol/L) or/and
• Impaired glucose tolerance (glucose levels ≥ 7.8 and ≤ 11.1 mmol/L, 2-hours after an OGTT or/and glucose levels ≥8.6 mmol/L, 1-hour after an OGTT)

Exclusion Criteria:

• Has been diagnosed with diabetes
• Having other conditions, like liver, pancreatic, cardiovascular, gastro-intestinal or endocrine diseases, that could influence the study results
• Use of medications or supplements that could influence the study results
• Sensitive to medical skin adhesives
• More than 5kg weight change in the past 12 weeks
• Excessive alcohol consumption (>21 glasses/week for men and >14 glasses/week for women on average)
• Being an employee of Wageningen University, division Human Nutrition and Health
• Currently a research subject in other research